Villaris Therapeutics is a biopharmaceutical company in the preclinical stage that is dedicated to the development of innovative antibody therapeutics for treating vitiligo. A recent breakthrough uncovered that an immune pathway, triggered by IL-15 signaling and the generation of autoimmune memory T cells (TRM), was accountable for the reoccurrence of vitiligo shortly after discontinuing treatments. Targeting this pathway with therapy proved to be highly effective in reversing the disease in a vitiligo mouse model, yielding long-lasting outcomes.